FinlandFinland

Superior process

07.03.2012

Finnish protein manufacturer Vectron Biosolutions AS has completed a study comparing different expression technologies. According to Vectron, their proprietary E. coli expression technology gave higher yields for seven out of ten tested bio­similar proteins, including interferons, several interleukins and insulin. The yield from fermentation increased from two- to sevenfold, whereas in insoluble fraction increases of up to 25-fold were reported. “Demonstrating that our technology is superior for the manufacture of many valuable therapeutic proteins is a major milestone for us,” commented CEO Trond Erik Vee Aune. The biosimilars market is highly competitive, which makes cost-efficient manufacturing processes essential.

FinlandFinland

03.11.2010

Turku/Freiburg – EU researchers led by scientists at the University of Turku have begun designing a bacterium able to produce liquefied petroleum gas (LPG) from sunlight. “We have all the parts to put the ability for production...

FinlandFinland

19.09.2010

Rajamäki/Darmstadt – A cooperation project between AB Enzymes Oy and Royal Oy has resulted in the discovery of an enzyme that enables washing temperature to be dropped to as low as 10° C. The project is being funded by the SymBio...

FinlandFinland

08.07.2010

Turku – Finland’s Faron Pharmaceuticals Ltd. has announced a cooperation with German biotech company Priaxon AG to create new scaffold structures to modify the AOC3-protein function and its ligand interaction with orally...

FinlandFinland

09.06.2010

Tampere – Short people are at greater risk of developing heart disease than tall people, according to a meta-analysis of 52 populations-based studies including 3 million people by Finnish researchers (Eur. Heart J.,...

FinlandFinland

12.05.2010

Reykjavik – Researchers from the Icelandic bio­tech company deCODE – together with colleagues from 23 institutions in a dozen countries – have determined that genetic factors influence both nico­tine dependence and the incidence...

FinlandFinland

11.05.2010

Turku – Finnish Biotie Therapies Corp. confirmed that its oral phospho­diesterase 4 inhibitor ELB353 has proven safe and pharmacologically active in a Phase I study. Pharmacokinetic data point to the suitability of ELB353 for a...

FinlandFinland

07.03.2010

Helsinki/Hinxton – Finland has pledged EUR1.85m to help create world-class bio­informatics, biobanking and translational research infrastructures, the European Bioinformatics Institute (EBI) at the European Molecular Laboratory...

FinlandFinland

04.02.2010

Helsinki –Finland is investing EUR1.9m in creating world class bioinformatics, biobanking and translational research infrastructures. The investment comes as part of the linkage of three large EU projects ELIXIR, BBMRI, and...

FinlandFinland

01.02.2010

Helsinki – The Academy of Finland is restructuring its funding instruments. The purpose of the reform, which will be finalised in fall 2010, is to give greater clarity and flexibility to Finnish researchers, and to improve the...

Displaying results 11 to 20 out of 96

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-finland/browse/1/article/superior-process.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.13 CHF4.68%
  • CO.DON3.15 EUR4.30%
  • BB BIOTECH146.25 EUR2.17%

FLOP

  • WILEX2.35 EUR-5.24%
  • SANTHERA89.15 CHF-3.10%
  • EVOTEC2.93 EUR-2.33%

TOP

  • CO.DON3.15 EUR26.0%
  • PAION3.01 EUR25.4%
  • SANTHERA89.15 CHF18.9%

FLOP

  • ADDEX3.13 CHF-21.7%
  • EVOTEC2.93 EUR-20.2%
  • MEDIGENE3.95 EUR-14.1%

TOP

  • SANTHERA89.15 CHF2085.0%
  • CO.DON3.15 EUR258.0%
  • PAION3.01 EUR198.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.67 EUR-40.4%
  • BIOFRONTERA2.18 EUR-40.3%

No liability assumed, Date: 18.09.2014


Current issue

All issues

Product of the week

Products